Masitinib (AB1010)

Masitinib (AB1010)は、組み換え型人間のキット(野生型)の阻害剤で、IC50 が 200 nMです。

目録号S1064
5 5 1レビュー 2製品表彰状
価格 在庫  
USD 103 In stock
USD 113 In stock
USD 214 In stock
USD 1096 In stock

Masitinib (AB1010) 化学構造
分子量: 498.64

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 Masitinib (AB1010)は、組み換え型人間のキット(野生型)の阻害剤で、IC50 が 200 nMです。
目標 Kit PDGFRα/β
IC50 200 nM 540 nM/800 nM [1]
In vitro試験 Masitinib is a competitive inhibitor against ATP at concentrations ≤500 nM. Masitinib also potently inhibits recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, Masitinib demonstrates weak inhibition of Abl and c-Fms. Masitinib more strongly inhibits degranulation, cytokine production, and bone marrow mast cell migration than imatinib. In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 µM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM. Masitinib also causes inhibition of SCF-stimulated tyrosine phosphorylation of human Kit in mastocytoma cell-lines and BMMC. Masitinib inhibits Kit gain-of-function mutants, including V559D mutant and Δ27 mouse mutant with IC50 of 3 and 5 nM in Ba/F3 cells. Masitinib inhibits the cell proliferation of mastocytoma cell lines including HMC-1α155 and FMA3 with IC50 of 10 and 30 nM, respectively. [1] Masitinib inhibits cell growth and PDGFR phosphorylation in two novel ISS cell lines, which suggest that Masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS. [2]
In vivo試験 Masitinib inhibits tumour growth and increases the median survival time in Δ27-expressing Ba/F3 tumor models at 30 mg/kg, without cardiotoxicity or genotoxicity. [1] Masitinib (12.5 mg/kg/d PO) increases overall TTP (time-to-tumor progression) compared with placebo in dogs. [3] The combination of masitinib/gemcitabine shows synergy in vitro on proliferation of gemcitabine-refractory cell lines Mia Paca2 and Panc1, and to a lesser extent on Mia Paca-2 pancreatic tumours in Nog璖CID mice. [4]
臨床試験 Currently in Phase III to compare the efficacy and the safety of Masitinib versus Placebo in the treatment of patients with severe persistent asthma treated with oral corticosteroids
特集 Potential low side-effect profile.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

In vitro enzyme-linked immunoassay with recombinant protein kinases A 96-well microtitre plateis coated overnight with 0.25 mg/ml poly(Glu,Tyr 4:1), rinsed twice with 250 µL of washing buffer (10 mM phosphate-buffered saline [pH 7.4] and 0.05% Tween 20) and dried for 2 hours at room temperature. Assays are performed at room temperature with a final volume of 50 µL in kinase buffer (10 mM MgCl2, 1 mM MnCl2, 1 mM sodium orthovanadate, 20 mM HEPES, pH 7.8) containing ATP at a concentration of at least twice the Km for each enzyme and an appropriate amount of recombinant enzyme to ensure a linear reaction rate. Reactions are initiated upon introduction of the enzyme and terminated with the addition of one reaction volume (50 μL) of 100 mM EDTA per 5 M urea mix. Plates are washed three times and incubated with 1:30,000 horseradish peroxidase-conjugated anti-phosphotyrosine monoclonal antibody, then washed three times and incubated with tetramethylbenzidine. The final reaction product is quantified by spectrophotometry at 450 nm.

細胞アッセイ: [1]

細胞系 Ba/F3 cells expressing wild-type or mutant human Kit, HMC1, HMC-1α155
濃度 0.1 nM - 10 μM
処理時間 48 hours
方法 For the assay of Ba/F3 cell proliferation, microtitre plates are seeded with a total of 104 cells/well in 100 μL of RPMI 1640 medium with 10% foetal bovine serum at 37 °C. These are supplemented, or not, with either 0.1% conditioned medium from X63-IL-3 cells or 250 ng/mL murine SCF. The murine SCF, which activates Kit, is purified from the conditioned medium of SCF-producing CHO cells. Cells are grown for 48 hours at 37 °C with Masitinib and then incubated with 10 μL/well of WST-1 reagent for 3 hours at 37 °C. The amount of formazan dye formed is quantified by its absorbance at 450 nm using a scanning multiwell spectrophotometer. A blank well without cells is used as a background control for the spectrophotometer.

動物実験: [1]

動物モデル Ba/F3 Δ27 tumour model in female MBRI Nu/Nu mice
製剤 DMSO
投薬量 30 mg/kg (intraperitoneal) or 10, 30, or 45 mg/kg (orally).
管理 Intraperitoneal or orally administered.
1

参考

化学情報

Download Masitinib (AB1010) SDF
分子量 498.64
化学式

C28H30N6OS

CAS No. 790299-79-5
別名 N/A
溶解度 (25°C)
  • DMSO 100 mg/mL
  • 水 <1 mg/mL
  • エタノール 4 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source , , Biomaterials, 2013, 34(38):9737-46. Masitinib (AB1010) purchased from Selleck
Method H&E staining
Cell Lines wild-type C57BL/6 mice
Concentrations
Incubation Time 14, 21, 28 days
Results H&E-stained tissue preparations exhibit variable distributions of different inflammatory and wound-recruited cell densities for both control and masitinib-releasing implant sites at each time point as shown in Figure. Densities of PMNs, macrophages, FBGCs, and fibroblasts were quantified as a function of distance from the implant surfaces. Cell densities up to distances of 300 μm from implant interfaces were considered in this analysis.

製品表彰状 (2)

  • Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib. [Avula MN, et al. Biomaterials 2013;34(38):9737-46]

    PubMed: 24060424
  • Foreign Body Response To Subcutaneous Biomaterial Implants in a Mast Cell-deficient Kitw-Sh Murine Model. [Avula M ,et al. Acta Biomater 2013;10.1016/j.actbio.2013.12.056]

    PubMed: 24406200

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related c-Kit 阻害剤

  • Linifanib (ABT-869)

    Linifanib(ABT-869)は、新しい、強力なATP競争的RTK阻害剤で、KDRCSF-1RFlt-1Flt-3に作用するとき、IC50がそれぞれ 4 nM、 3 nM、 3 nM 、3 nMになる。

  • Axitinib

    Axitinibは、マルチターゲット阻害剤で、 VEGFR1VEGFR2VEGFR3、 PDGFRβ 、c-Kit に作用する時、IC50 がそれぞれ 0.1 nM、0.2 nM、0.1-0.3 nM、 1.6 nM 、1.7 nMになる。

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120)は三重血管キナーゼ阻害剤、VEGFR1, VEGFR2, VEGFR3 を作用すると、 IC50 がそれぞれ 34 nM, 5 nM 、 5 nMとなる。Phase 2.

  • Dovitinib (TKI-258, CHIR-258)

    Dovitinib (TKI-258, CHIR-258)は非常に強い、新型の多い標的阻害剤、FLT3、c - kit、受容体、マウス/2/3、成長因子受容体と球コロニー刺激因子受容体ßに作用する時、IC50がそれぞれ 1 nM, 2 nM, 5 nM, 10 nM, 8 nM, 27 nM と 36 nMになる。

  • Dasatinib

    Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) は口でImatinibの生物学的利用能メシラート塩です。そして、それは v-Ablc-KitPDGFRのマルチターゲット阻害剤で、IC50 がそれぞれ 0.6 μM、 0.1 μM、 0.1 μMです。

  • Motesanib Diphosphate (AMG-706)

    Motesanib Diphosphate (AMG-706)は、VEGFR1/2/3、PDGFR、c-キットと浸水の強力なATP競争的阻害剤で、 IC50 がそれぞれ 2 nM、 3 nM、 6 nM、 84 nM、 8 nM 、59 nMです。

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl)は、VEGFR-1、VEGFR-2、VEGFR-3、PDGFR、FGFR、c-キットとc-fmsの新しいマルチターゲットの阻害剤で、IC50 がそれぞれ 10 nM、 30 nM、 47 nM、 84 nM、 74 nM、 140 nM 、146 nMです。Phase 2

  • Sorafenib Tosylate

    Sorafenib Tosylateは、Raf-1、B-RafとVEGFR-2のマルチキナーゼ阻害剤で、IC50 がそれぞれ 6 nM、 22 nM、90 nMです。Phase 4

  • Sunitinib Malate

    Sunitinib Malate は、VEGFR2(Flk-1)とPDGFRβを目標としている強力なRTK阻害剤で、IC50 がそれぞれ 80 nM 、2 nMです。

最近見られたアイテム

Tags: Masitinib (AB1010)を買う | Masitinib (AB1010)供給者 | Masitinib (AB1010)を購入する | Masitinib (AB1010)費用 | Masitinib (AB1010)生産者 | オーダーMasitinib (AB1010) | Masitinib (AB1010)代理店
お問い合わせ